Table 3.

Number of nucleotide substitutions in the full genome and various regions of hepatitis B virus (HBV) in the non‐hepatocellular carcinoma (HCC) and HCC group

	Full genome	pre‐S1	pre‐S2	S	pre‐C/core	X	Pol	Enhancer I	Enhancer II	X promoter	core promoter	S1 promoter	S2 promoter
	(nt 0–3215)	(nt 2484–3204)	(nt 3205–154)	(nt 155–835)	(nt 1814–2452)	(nt 1376–1846)	(nt 2307–1620)	(nt 1060–1260)	(nt 1635–1714)	(nt1230–1376)	(nt 1519–1822)	(nt 2710–2800)	(nt 2960–3180)
Non‐HCC group (B)	68.35 ± 20.90	9.15 ± 3.73	4.40 ± 2.19	5.30 ± 2.16	10.30 ± 5.40	9.05 ± 3.25	54.55 ± 15.51	8.15 ± 3.05	1.70 ± 0.92	6.10 ± 1.99	5.30 ± 2.70	1.75 ± 1.12	7.95 ± 3.07
Non‐HCC group (A)	71.85 ± 21.64	9.75 ± 3.58	4.65 ± 2.28	6.05 ± 2.19	12.55 ± 5.67	8.90 ± 2.56	56.30 ± 16.70	7.65 ± 2.70	1.60 ± 0.88	6.05 ± 1.88	5.35 ± 1.93	1.85 ± 1.50	8.20 ± 2.89
HCC group (B)	76.13 ± 11.59	10.26 ± 2.14	3.78 ± 1.93	5.74 ± 1.60	13.00 ± 5.75	9.69 ± 1.87	59.04 ± 8.23	8.09 ± 2.15	1.83 ± 0.98	7.26 ± 1.66	5.48 ± 1.44	1.78 ± 0.85	9.04 ± 1.36
HCC group (A)	80.26 ± 17.74	10.61 ± 2.87	4.39 ± 2.43	6.52 ± 3.87	14.52 ± 6.49	9.91 ± 2.71	61.65 ± 13.14	7.96 ± 1.99	1.70 ± 0.82	7.04 ± 1.92	5.43 ± 1.56	2.26 ± 1.39	9.61 ± 2.02
P (non‐HCC B vs HCC B)	0.14	0.27	0.55	0.47	0.18	0.21	0.23	0.81	0.62	0.07	0.66	0.87	0.16
P (non‐HCC A vs HCC A)	0.20	0.57	0.43	0.61	0.25	0.39	0.31	0.75	0.95	0.06	0.88	0.35	0.12

The significance of differences (P‐value) in the indicated groups is shown. The number of nucleotide (nt) substitutions (mean±SD) in the full genome and the indicated regions of HBV are shown. Non‐HCC group (B): at the beginning of follow‐up in patients who did not develop HCC. Non‐HCC group (A): at the end of follow‐up in patients who did not develop HCC. HCC group (B): at the beginning of follow‐up in patients who developed HCC. HCC group (A): at the diagnosis of HCC in patients who developed HCC.